Abbott Laboratories
Prix: 88.18Entreprise et modèle économique
Abbott Laboratories is a global healthcare company that develops and manufactures a wide range of medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Its core products include glucose monitoring systems, heart devices, and nutritional supplements. Major business segments consist of Medical Devices, Diagnostics, Nutrition, and Pharmaceuticals, with significant revenue generated from diabetes care and diagnostic solutions.
Profil d’investissement
The stock presents a balanced investment profile, appealing to investors seeking moderate growth and income through dividends. With a dividend yield of 2.7%, it offers some income potential while maintaining a focus on stability. The company’s established market position and diversified product offerings contribute to its resilience, making it suitable for investors with a medium to long-term horizon.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 3.60 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -2.6% ↓
- Surprise BPA
- 0.0% conforme
- Volatilité 20 j
- 1.7% stable
- Rendement du dividende
- 2.7% modéré dernière date ex-dividende: 2026-04-15
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-05-20 02:33 | Conserver | Vendre | Weak momentum and high risk; hold for dividends. |
| 2026-05-08 14:56 | — | Conserver | Weak momentum and high risk; cautious approach advised. |
| 2026-05-08 06:44 | Conserver | Conserver | Компания испытывает значительное снижение цен на акции в последние месяцы, однако дивидендная доходность остается привлекательной. Рекомендуется удерживать акции до улучшения рыночной ситуации. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-04-22 00:25 | Daiwa | Note abaissée | — → 92 | 92.745 |
| 2026-04-20 09:47 | Barclays | Objectif abaissé | 144 → 143 | 96.83 |
| 2026-04-17 11:52 | UBS | Objectif abaissé | 132 → 115 | 95.46 |
Rien pour le moment